Clinical Trial Update: Safety Study of Anti-Asthma Agent BMEC-1217B [Phase 1]

View source ↗

Summary

Phase 1 safety study of the anti-asthma agent BMEC-1217B conducted by Medigreen Biotechnology Corp. for asthma; the study status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BMEC-1217B

Snippet

Sponsor: Medigreen Biotechnology Corp. | Conditions: Asthma | Phase 1 | Status: UNKNOWN